
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics is a promising late-stage biopharmaceutical company with a positive outlook on its stock. The potential of its lead drug candidate, cadisegliatin, in treating type 1 and type 2 diabetes, along with its projected peak sales of $650M and its exploration of partnerships for commercialization, make it a strong investment opportunity. Additionally, the experience and backgrounds of the company's CEO and CFO add credibility to its success potential.
Bears say
vTv Therapeutics is facing several challenges, including its dependence on one main drug candidate, CATT1, for potential revenue, and the need for additional trials beyond CATT1 for FDA approval. Its real-world adoption may also be limited due to competition and regulatory scrutiny for oral adjunctive therapies. Additionally, the company has faced issues with clinical holds and potential intellectual property risks, which could impact its future success. All of these factors contribute to a negative outlook for vTv Therapeutics from a financial analyst's perspective.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares